Teva Pharmaceutical Industries Ltd banner

Teva Pharmaceutical Industries Ltd
TASE:TEVA

Watchlist Manager
Teva Pharmaceutical Industries Ltd Logo
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Watchlist
Price: 9 370 ILS -0.84% Market Closed
Market Cap: ₪105.5B

Teva Pharmaceutical Industries Ltd
Stock-Based Compensation

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Teva Pharmaceutical Industries Ltd
Stock-Based Compensation Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Stock-Based Compensation CAGR 3Y CAGR 5Y CAGR 10Y
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Stock-Based Compensation
$157m
CAGR 3-Years
8%
CAGR 5-Years
4%
CAGR 10-Years
3%
Sol Gel Technologies Ltd
NASDAQ:SLGL
Stock-Based Compensation
$82k
CAGR 3-Years
-62%
CAGR 5-Years
-42%
CAGR 10-Years
N/A
PolyPid Ltd
NASDAQ:PYPD
Stock-Based Compensation
$4.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mediwound Ltd
NASDAQ:MDWD
Stock-Based Compensation
$3.1m
CAGR 3-Years
17%
CAGR 5-Years
19%
CAGR 10-Years
2%
S
Seach Medical Group Ltd
TASE:SEMG
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Stock-Based Compensation
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Teva Pharmaceutical Industries Ltd
Glance View

Teva Pharmaceutical Industries Ltd., a titan in the global pharmaceutical landscape, has navigated the intricate world of pharmaceuticals with a blend of strategic vision and operational efficiency. Founded in 1901 and headquartered in Israel, Teva has become synonymous with the production of affordable generic medications, a key pillar of its business model. The company's narrative is one of adaptability and foresight, having positioned itself as a leader in the generic drug sector by leveraging economies of scale and a vast distribution network. By acquiring and integrating smaller pharmaceutical firms over the years, Teva has expanded its portfolio to include a vast array of treatments that address a broad spectrum of therapeutic areas. This strategic expansion has enabled the company to offer nearly the same efficacy as brand-name drugs at a fraction of the cost, thus capturing significant market share and delivering value to both patients and healthcare systems worldwide. Beyond its prowess in generics, Teva has carved a niche in the specialty medicines market, focusing on innovative therapies that address complex conditions such as multiple sclerosis, migraine, and movement disorders. This dual-track approach to growth allows Teva to balance the volume-driven nature of the generics market with the higher margins offered by specialty drugs. The synthesis of these two facets – comprehensive generic offerings and targeted specialty pharmaceuticals – underpins Teva's revenue streams. Through a combination of robust pipeline development, strategic partnerships, and a commitment to operational excellence, Teva navigates the challenges of a competitive industry marked by ever-evolving regulations and pricing pressures, striving to maintain its status as a reliable provider of healthcare solutions on a global scale.

TEVA Intrinsic Value
4 992.69 ILS
Overvaluation 47%
Intrinsic Value
Price ₪9 370

See Also

What is Teva Pharmaceutical Industries Ltd's Stock-Based Compensation?
Stock-Based Compensation
157m USD

Based on the financial report for Dec 31, 2025, Teva Pharmaceutical Industries Ltd's Stock-Based Compensation amounts to 157m USD.

What is Teva Pharmaceutical Industries Ltd's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
3%

Over the last year, the Stock-Based Compensation growth was 28%. The average annual Stock-Based Compensation growth rates for Teva Pharmaceutical Industries Ltd have been 8% over the past three years , 4% over the past five years , and 3% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett